<DOC>
	<DOC>NCT00000625</DOC>
	<brief_summary>To determine the efficacy and safety of zidovudine ( AZT ) versus didanosine ( ddI ), AZT plus ddI, and AZT plus zalcitabine ( ddC ) in preventing disease progression in HIV-infected patients with CD4 counts of 200-500 cells/mm3.</brief_summary>
	<brief_title>A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3</brief_title>
	<detailed_description>Patients are randomized to receive AZT alone, AZT and ddI, AZT and ddC, or ddI alone for at least 2 years. Patients who develop AIDS or whose CD4 count falls to 50 percent or less of baseline are crossed over to another treatment arm. PER AMENDMENT 4/5/95: Study treatment will be available until 10/31/95 at the latest for patients still taking study medications on 4/30/95, so that follow-up trials may be completed and approved.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: PCP prophylaxis, M. tuberculosis prophylaxis, short courses of acyclovir, chronic suppressive acyclovir, pneumovax or Hib vaccine, antibiotics, rEPO and GCSF for grade 3 or worse anemia and neutropenia, systemic corticosteroids for &lt; 21 days, regularly prescribed medications, and vitamins or herbal therapies. Patients must have: HIV infection without AIDS with CD4 200500 cells/mm3. PER AMENDMENT 4/5/95: Patients must have remained on ACTG 175 study treatment through 4/30/95 and meet toxicity management criteria for continuing treatment. Subjects taking ACTG 175 crossover treatment are eligible. Exclusion Criteria Coexisting Condition: Patients with the following conditions are excluded: Current AIDSrelated condition other than minimal KS, grade 2 or worse peripheral neuropathy, and malignancy requiring systemic therapy. Concurrent Medication: Excluded: Other antiHIV drugs, biologic response modifiers other than rEPO and GCSF, systemic cytotoxic chemotherapy, chronic systemic corticosteroids, or any drug that affects AZT glucuronidation or clearance. Concurrent Treatment: Excluded: Radiotherapy other than limited local therapy to skin. Patients with the following prior conditions are excluded: AIDSrelated condition other than minimal KS; intolerance to AZT, ddI, or ddC at study doses; and acute or chronic pancreatitis. Prior Medication: Excluded: Acute therapy for an infection or other medical illness within the past 14 days. Current alcohol abuse.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>